Suzhou Siran Biotech

Suzhou Siran Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary lipid nanoparticle (LNP) delivery platform and advanced mRNA sequence optimization technologies to address unmet needs in infectious diseases, oncology, and rare genetic disorders. Its lead program, SRN-001, is an mRNA vaccine candidate targeting COVID-19 that has progressed into clinical evaluation. Siran Biotech is supported by prominent venture capital investors and operates integrated R&D and pilot manufacturing facilities to accelerate the translation of programmable medicines. The company's strategic focus includes both prophylactic vaccines and therapeutic protein replacement therapies.